摘要
本文根据脑血管造影评价再灌注程度,提出了比格犬颅内血栓性大血管闭塞药物溶栓评价方法。采用自体血栓经颈内动脉推入方法,建立比格犬颅内大血管闭塞模型,以血管数字减影技术(DSA)进行血管显影,并将血流再灌注程度分为0级、Ⅰ级、Ⅱa级、Ⅱb级和Ⅲ级5个等级,并进行相应评分:0级代表无灌注(1分);Ⅰ级为极微量灌注(2分);Ⅱa级为小于二分之一灌注(3分);Ⅱb级为大于二分之一灌注(4分);Ⅲ级为完全灌注(5分)。以阿替普酶溶栓药物对方法量化指标进行验证。结果显示,模型组100%达到Ⅰ级及以下水平;阿替普酶组83%达到Ⅱa及以上水平。秩和检验分析结果表明,阿替普酶显著促进闭塞脑血管灌注再通。该动物实验已经通过中国医学科学院药物研究所实验动物管理与动物福利委员会批准。通过以上方式建立犬血栓性颅内大血管闭塞药物溶栓药效评价方法,为溶栓药物临床前药效评价提供技术支持。
We provide a new preclinical pharmacodynamic evaluation method of cerebral thrombolytics using beagle dogs with acute thrombotic cerebrovascular occlusion.An intracranial large vessel occlusion animalmodel was generated by pushing an autologous thrombus to the left carotid artery under X-ray angiography.The experiments were approved by the Animal Care and Welfare Committee Institute of Materia Medica,China Academy of Medical Sciences(CAMS),Peking Union Medical College.According to the degrees of cerebral blood flow reperfusion,the new method has 0,Ⅰ,Ⅱ(Ⅱa andⅡb),Ⅲlevels.Respectively,0 level represents no blood flow through the area of vascular occlusion;Ⅰlevel has low perfusion;Ⅱa level is less than half the infusion;Ⅱb level is more than half perfusion;Ⅲlevel is completely recanalization perfusion.Alteplase was used as a positive drug to verify the accuracy of the method.Our results suggest that 100%of dogs reached the level of grade I and below in the model group,while 83%reached the level of grade IIa and above in the alteplase group.Results of a rank sum test showed that alteplase significantly improved the reperfusion of occluded cerebral vessels.We propose a method to evaluate the efficacy of thrombolytic drugs on dogs with middle cerebral artery occlusion.
作者
张鹏
田毅
马高亭
董超然
王明超
周建明
曹亮
朱海波
ZHANG Peng;TIAN Yi;MA Gao-ting;DONG Chao-ran;WANG Ming-chao;ZHOU Jian-ming;CAO Liang;ZHU Hai-bo(State Key Laboratory for Bioactive Substances and Functions of Natural Medicines,Beijing Key Laboratory of New DrugMechanisms and Pharmacological Evaluation Study,Institute ofMateriaMedica,Chinese Academy ofMedical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China;Jiangsu Kanion Pharmaceutical Company,Lianyungang 222067,China)
出处
《药学学报》
CAS
CSCD
北大核心
2021年第10期2797-2801,共5页
Acta Pharmaceutica Sinica
基金
国家“十三五重大新药创制”科技重大专项(2018ZX09711001-003-01)。